DE69839263T2 - Hämoglobin-Mutanten mit verringertem Stickstoff(mon)oxid-Entfernungsvermögen - Google Patents

Hämoglobin-Mutanten mit verringertem Stickstoff(mon)oxid-Entfernungsvermögen Download PDF

Info

Publication number
DE69839263T2
DE69839263T2 DE69839263T DE69839263T DE69839263T2 DE 69839263 T2 DE69839263 T2 DE 69839263T2 DE 69839263 T DE69839263 T DE 69839263T DE 69839263 T DE69839263 T DE 69839263T DE 69839263 T2 DE69839263 T2 DE 69839263T2
Authority
DE
Germany
Prior art keywords
leu
trp
val
phe
hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839263T
Other languages
German (de)
English (en)
Other versions
DE69839263D1 (de
Inventor
Michael J. San Diego WEICKERT
Christopher B. Louisville GLASCOCK
Antony J. Boulder MATHEWS
Douglas D. Louisville LEMON
Daniel H. Boulder DOHERTY
John S. Houston OLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Biotech Technology SARL
Rice University
Original Assignee
Baxter Biotech Technology SARL
Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Biotech Technology SARL, Rice University filed Critical Baxter Biotech Technology SARL
Application granted granted Critical
Publication of DE69839263D1 publication Critical patent/DE69839263D1/de
Publication of DE69839263T2 publication Critical patent/DE69839263T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69839263T 1997-05-02 1998-05-01 Hämoglobin-Mutanten mit verringertem Stickstoff(mon)oxid-Entfernungsvermögen Expired - Lifetime DE69839263T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4536497P 1997-05-02 1997-05-02
US45364P 1997-05-02
US5798697P 1997-09-05 1997-09-05
US57986P 1997-09-05
PCT/US1998/008861 WO1998050430A2 (en) 1997-05-02 1998-05-01 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging

Publications (2)

Publication Number Publication Date
DE69839263D1 DE69839263D1 (de) 2008-04-30
DE69839263T2 true DE69839263T2 (de) 2009-04-30

Family

ID=26722688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839263T Expired - Lifetime DE69839263T2 (de) 1997-05-02 1998-05-01 Hämoglobin-Mutanten mit verringertem Stickstoff(mon)oxid-Entfernungsvermögen

Country Status (7)

Country Link
US (2) US6455676B1 (enExample)
EP (1) EP0979279B1 (enExample)
JP (2) JP4512673B2 (enExample)
AU (1) AU750295B2 (enExample)
CA (1) CA2299049C (enExample)
DE (1) DE69839263T2 (enExample)
WO (1) WO1998050430A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
JP4563679B2 (ja) * 2001-12-06 2010-10-13 デューク ユニバーシティ 形成外科における組織弁壊死の予防
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US20070166792A1 (en) * 2004-09-15 2007-07-19 Olson John S Increasing hemoglobin and other heme protein production in bacteria by co-expression of heme transport genes
WO2006031992A2 (en) * 2004-09-15 2006-03-23 William Marsh Rice University Increasing hemoglobin and other heme protein production in bacteria by co-expression of heme transport genes
US7642233B2 (en) * 2004-09-15 2010-01-05 William Marsh Rice University Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein
US20060195064A1 (en) * 2005-02-28 2006-08-31 Fresenius Medical Care Holdings, Inc. Portable apparatus for peritoneal dialysis therapy
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
EP3252128B1 (en) * 2006-04-03 2019-01-02 Pharmatherm Chemicals Inc. Thermal extraction method for producing a taxane extract
EP2463295A1 (en) 2006-05-22 2012-06-13 The Regents of The University of California Compositions and methods for the delivery of oxygen
US7905990B2 (en) 2007-11-20 2011-03-15 Ensyn Renewables, Inc. Rapid thermal conversion of biomass
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
WO2011008858A1 (en) 2009-07-15 2011-01-20 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) * 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
US8499702B2 (en) 2010-07-15 2013-08-06 Ensyn Renewables, Inc. Char-handling processes in a pyrolysis system
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
US9694125B2 (en) 2010-12-20 2017-07-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
CN103648540B (zh) 2011-04-21 2016-06-01 弗雷塞尼斯医疗保健控股公司 医疗流体泵送系统及相关装置和方法
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
JP6389125B2 (ja) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
US9109177B2 (en) 2011-12-12 2015-08-18 Ensyn Renewables, Inc. Systems and methods for renewable fuel
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
FR3002146B1 (fr) * 2013-02-15 2016-03-04 Hemarina Utilisation d'hemoglobine d'annelides pour traiter les cancers
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5545727A (en) 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5844090A (en) 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
JPH09506332A (ja) 1993-09-14 1997-06-24 メディカル リサーチ カウンセル ヘモグロビンの改良またはヘモグロビンに関する改良
US5665869A (en) 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5843888A (en) * 1995-05-01 1998-12-01 Carnegie Mellon University Low oxygen affinity mutant hemoglobin
WO1997004110A1 (en) * 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
WO1997015591A1 (en) * 1995-10-23 1997-05-01 Rice University Hemoglobin mutants that reduce heme loss
WO1997023631A2 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains

Also Published As

Publication number Publication date
US20030017537A1 (en) 2003-01-23
EP0979279A2 (en) 2000-02-16
US7049406B2 (en) 2006-05-23
JP2008194051A (ja) 2008-08-28
JP4399634B2 (ja) 2010-01-20
AU750295B2 (en) 2002-07-11
AU7275898A (en) 1998-11-27
JP4512673B2 (ja) 2010-07-28
WO1998050430A3 (en) 1999-04-01
WO1998050430A2 (en) 1998-11-12
CA2299049C (en) 2008-07-15
DE69839263D1 (de) 2008-04-30
US6455676B1 (en) 2002-09-24
CA2299049A1 (en) 1998-11-12
JP2002507115A (ja) 2002-03-05
EP0979279B1 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
EP0979279B1 (en) Hemoglobin mutants with reduced nitric oxide scavenging
DE69034091T2 (de) Herstellung von Hämoglobin und Analogen davon in Nicht-Erythrozytzellen
DE69225978T2 (de) Verfahren zur herstellung und anwendung von multimeren hämoblobinen
AU784195B2 (en) Reduced side-effect hemoglobin compositions
DE69233474T2 (de) Pharmazeutische Zusammensetzung enthaltend S-Nitrosoimmunoglobuline und Verwendung davon
EP0912197B1 (de) Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel
US6184356B1 (en) Production and use of multimeric hemoglobins
EP0376156A2 (de) Neue Insulinderivate, Verfahren zu deren Herstellung, ihre Verwendung und eine sie enthaltende pharmazeutische Zubereitung
EP0401508A2 (de) Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE69408677T2 (de) Nickelfreier hämoglobin und verfahren zu seiner herstellung
US5844090A (en) Modified hemoglobin-like compounds
US6812328B2 (en) Low oxygen affinity mutant hemoglobins
DE68923613T2 (de) Superoxid-dismutaseanaloge mit neuen bindeeigenschaften.
DE69737214T2 (de) Verfahren zur Kontrolle der Bildung von Beta-Dimeren bei Hämoglobin
EP1950298A2 (en) Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
WO1991013158A1 (en) Protein production in yeast
CA2618690A1 (en) Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging

Legal Events

Date Code Title Description
8364 No opposition during term of opposition